SCHEMBL7150850

SCHEMBL7150850

CC(C)(C)OC(=O)N[C@@H](CCCCN)C(=O)OC(C)(C)C

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSK P43235 4/20 0.49
ITGB3 P05106 8/20 0.48
ITGA2B P08514 8/20 0.48
CTSS P25774 3/20 0.47
TDP1 Q9NUW8 3/20 0.45
ATM Q13315 1/20 0.45
HDAC4 P56524 2/20 0.44
HDAC1 Q13547 2/20 0.44
HDAC6 Q9UBN7 1/20 0.44
MEN1 O00255 1/20 0.43
POLB P06746 1/20 0.43
KMT2A Q03164 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
P2RY2 P41231 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
HTT P42858 1/20 0.42
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23608150 1.00 CTSK (0.49) CTSKITGB3ITGA2BCTSSTDP1
SCHEMBL1304236 1.00 CTSK (0.49) CTSKITGB3ITGA2BCTSSTDP1
SCHEMBL30361337 0.98 CTSK (0.48) CTSKITGB3ITGA2BCTSSTDP1
Hydrochloric Acid SCHEMBL17309873 0.98 CTSK (0.48) CTSKITGB3ITGA2BCTSSTDP1
Hydrochloric Acid SCHEMBL8376069 0.98 CTSK (0.48) CTSKITGB3ITGA2BCTSSTDP1
Acetic Acid SCHEMBL11204426 0.96 ITGB3 (0.48) CTSKITGB3ITGA2BCTSSTDP1
SCHEMBL17603548 0.95 CTSK (0.50) CTSKITGB3ITGA2BCTSSTDP1
SCHEMBL3697925 0.95 CTSK (0.50) CTSKITGB3ITGA2BCTSSTDP1
SCHEMBL27603642 0.95 CTSK (0.50) CTSKITGB3ITGA2BCTSSTDP1
SCHEMBL17445176 0.94 CTSK (0.49) CTSKITGB3ITGA2BCTSSTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117820636-B Enzyme-responsive cytotoxic polyamino acid, and preparation method and application thereof 中国科学院长春应用化学研究所 2024-05-24 CN claimed
CN-117820636-A Enzyme-responsive cytotoxic polyamino acid, and preparation method and application thereof 中国科学院长春应用化学研究所 2024-04-05 CN claimed
CN-115304516-A Compounds with unconventional chromophores, their preparation and use 四川大学 2022-11-08 CN claimed
WO-2026107208-A1 COMPOSITIONS AND METHODS FOR TREATING MICROBIAL INFECTIONS THE METHODIST HOSPITAL (US) 2026-05-21 WO disclosed
US-20260117274-A1 ORTHOGONALLY CROSSLINKED PROTEINS, METHODS OF MAKING, AND USES THEREOF UNIV NEW YORK STATE RES FOUND (US) 2026-04-30 US disclosed
US-12577197-B2 Methods of preparing N6-((2-azidoethoxy)carbonyl)lysine SANOFI (FR) 2026-03-17 US disclosed
US-20260021192-A1 PROTEINS HAVING A COVALENT WARHEAD TOPAZ THERAPEUTICS INC (US) 2026-01-22 US disclosed
CN-121318852-A Preparation method and application of myogastric erosive agent 河南省农业科学院 2026-01-13 CN disclosed
EP-4663205-A1 POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF Shanghai Best-Link Bioscience, LLC (CN) 2025-12-17 EP disclosed
EP-4651910-A1 DUAL LABELLED COMPOUNDS TARGETING THE PROSTATE SPECIFIC MEMBRANE ANTIGEN Centre Hospitalier Universitaire Vaudois (CHUV) (CH) 2025-11-26 EP disclosed
WO-2025230475-A1 BETA-SILYL ALKYNOATES: VERSATILE REAGENTS FOR BIOCOMPATIBLE AND SELECTIVE AMIDE BOND FORMATION NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2025-11-06 WO disclosed
US-6482849-B1 Inhibitors of α4β1 mediated cell adhesion TANABE SEIYAKU CO., LTD. (JP) 2002-11-19 US disclosed
EP-0632040-A1 Antibacterial imidazole derivatives Takeda Chemical Industries, Ltd. (JP) 1995-01-04 EP disclosed
US-5223627-A Using a 4-nitro-2,1,3-benzoxadiazole compound ABBOTT LABORATORIES (US) 1993-06-29 US disclosed
EP-0253271-B1 FLUORESCENCE POLARIZATION METHOD FOR MONITORING FETAL LUNG MATURITY ABBOTT LABORATORIES (US) 1993-06-02 EP disclosed
US-4784961-A NITROAMINO BENZOXADIAZOLE DERIVATIVE FLUORESCENT COMPOUNDS ABBOTT LABORATORIES (US) 1988-11-15 US disclosed
EP-0127235-B1 PARTIALLY RETRO-INVERTED DECAPEPTIDE AS A SPECIFIC RENIN INHIBITOR WITH HIGH RESISTANCE TO ENZYMATIC HYDROLYSIS ENI-Ente Nazionale Idrocarburi (IT) 1988-10-19 EP disclosed
EP-0253271-A1 Fluorescence polarization method for monitoring fetal lung maturity ABBOTT LABORATORIES (US) 1988-01-20 EP disclosed
US-4585586-A HYPOTENSIVE ENTE NAZIONALE IDROCARBURI (IT) 1986-04-29 US disclosed
EP-0127235-A2 Partially retro-inverted decapeptide as a specific renin inhibitor with high resistance to enzymatic hydrolysis ENI-Ente Nazionale Idrocarburi (IT) 1984-12-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260117274-A1 ORTHOGONALLY CROSSLINKED PROTEINS, METHODS OF MAKING, AND USES THEREOF PTMS, PSMG3, PSMB3 CTSK 3616/4885ITGB3 765/4885ITGA2B 3259/4885
US-12577197-B2 Methods of preparing N6-((2-azidoethoxy)carbonyl)lysine JMJD6, PHF2, KDM2A CTSK 1304/4885ITGB3 1688/4885ITGA2B 1841/4885
US-20260021192-A1 PROTEINS HAVING A COVALENT WARHEAD RIOX2, ORC3, DCLRE1A CTSK 4297/4885ITGB3 443/4885ITGA2B 433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.